Theratarget

West Pharmaceutical Service Inc in Salt Lake City, UT is a leading provider of pharmaceutical drug supply solutions, offering a wide range of products and services to promote efficiency, reliability, and safety. Their product portfolio includes vial containment solutions, prefillable systems, self-injection devices, cartridge systems, and specialty components, all designed to meet the needs of the pharmaceutical industry. With a focus on quality enhancements and innovative technologies, West is committed to helping their customers reduce time to market and total cost of ownership, while ensuring the highest standards of product integrity and patient safety. Partnering with customers, West also offers a range of services and solutions, including analytical services, contract manufacturing, assembly, packaging solutions, design development, and engineering. They provide comprehensive support throughout the drug handling process, from program management to regulatory support, extractables and leachables analysis, and container closure integrity testing. With a strong emphasis on advanced therapies and combination products, West is dedicated to de-risking the transition to new drug delivery systems and supporting the pharmaceutical industry in meeting its next milestones.Generated from the website

Tci International is a company based in Salt Lake City, UT, specializing in providing a range of international services to its clients. With a focus on global connections and expertise, Tci International offers solutions tailored to meet the unique needs of businesses operating on an international scale. Generated from their business information

GlycoMira Therapeutics is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT, dedicated to transforming cancer therapy and improving patient outcomes. Their innovative approach involves developing innate immune system modulators based on naturally occurring polysaccharides within the body. With a deep commitment to scientific integrity and dedicated perseverance, GlycoMira's team is focused on developing their lead drug candidate, GM-1111, which has shown promising potential in addressing unmet needs in solid tumor treatment and supportive care. Supported by grant awards from the National Institutes of Health and private investments, GlycoMira aims to revolutionize the treatment of cancer and other inflammatory diseases.Generated from the website